Medication info
Glufapex SR Tablets 500mg (Metformin Hydrochloride)

Glufapex SR Tablets 500mg (Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Darim Biotech Co., Ltd.
Appearance
White, oblong, extended-release film-coated tablet
Packaging
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202301018 · Approved 2023.03.23 · Insurance code 664602800

Summary

Main use
Treatment of type 2 diabetes mellitus in adults
Who takes it
Adults
Adult dose
The dose should be determined individually based on drug efficacy and tolerability and should not exceed the recommended maximum daily dose. - The usual initial dose is metformin hydrochloride extended-release tablets 500mg once daily with the evening meal. - Measure blood glucose levels after one week and adjust the dose. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase by 500mg each week. Up to a maximum of 2000mg per day may be administered with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. - At initiation of treatment and during dose adjustment, fasting blood glucose should be measured to assess the response to this medication and identify the minimum effective dose. Glycated hemoglobin levels should be measured approximately every 3 months. - The goal of treatment with this medication, whether used as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medication may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment: - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, this medication must be discontinued immediately.

Ingredients

Manufacturer
Darim Biotech Co., Ltd.

Efficacy & effects

Treatment of type 2 diabetes mellitus in adults

  • Poor blood sugar control
  • type 2 diabetes
  • overweight
View approved original text

This medication is used for adults with type 2 diabetes who have difficulty controlling blood sugar levels through diet and exercise alone, particularly for those who are overweight. It can be used alone or in combination with other oral hypoglycemic agents or insulin to help control blood sugar levels effectively. This contributes to achieving better blood sugar control.

How to take

Adult dose

The dose should be determined individually based on drug efficacy and tolerability and should not exceed the recommended maximum daily dose. - The usual initial dose is metformin hydrochloride extended-release tablets 500mg once daily with the evening meal. - Measure blood glucose levels after one week and adjust the dose. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase by 500mg each week. Up to a maximum of 2000mg per day may be administered with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. - At initiation of treatment and during dose adjustment, fasting blood glucose should be measured to assess the response to this medication and identify the minimum effective dose. Glycated hemoglobin levels should be measured approximately every 3 months. - The goal of treatment with this medication, whether used as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medication may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment: - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, this medication must be discontinued immediately.

Precautions

This medication can rarely cause a serious condition known as lactic acidosis. Lactic acidosis is a condition where lactic acid builds up in the body and can lead to acidification, which can be life-threatening if severe. Therefore, caution is necessary. Additionally, when this medication is used with insulin or sulfonylurea medications, significant hypoglycemia may occur, so blood sugar levels should be monitored closely. This medication is not to be administered to patients with moderately severe or greater renal impairment, dehydration, severe infection, or acute diseases that affect renal function. In cases of acute or unstable heart failure, this medication should be discontinued before and after examinations using iodinated contrast agents, and can only be resumed once renal function is confirmed to be normal. Patients with an allergy to any component of this medication, individuals with type 1 diabetes, diabetic ketoacidosis, severe infections, liver dysfunction, severe gastrointestinal disorders, and patients with excessive alcohol intake should also not take this medication. Patients with irregular eating habits, strenuous exercise, or those taking interacting medications should be treated cautiously for the risks of lactic acidosis and hypoglycemia. During the use of this medication, vitamin B12 deficiency may occur, so regular blood tests should be performed to check vitamin B12 levels. Gastrointestinal symptoms are common at the beginning of treatment but generally subside over time. If symptoms are severe, consult a doctor. Renal function is closely related to the excretion of this medication, so regular renal function tests should be conducted before and during treatment. If renal function deteriorates, the medication should be discontinued. Taking this medication with alcohol increases the risk of lactic acidosis, so excessive drinking should be avoided during its use. There have been no reports of effects on the fetus when used during pregnancy, however, pregnant women at risk for placental dysfunction or preeclampsia should not use it, and breastfeeding mothers are also advised against taking this medication. Elderly patients often have decreased renal function, so dosage adjustments and frequent monitoring of renal function are necessary. In cases of overdose, the medication can be removed through blood dialysis, so if suspected, an immediate visit to a medical institution is required. This medication may interact with other diabetes treatments; therefore, it is essential to inform your doctor or pharmacist about any other medications you are taking. When taking the tablets, do not chew or crush; swallow them whole, and while the tablet coating may be excreted, this is a normal occurrence. Finally, during treatment with this medication, regular checks of blood sugar, glycosylated hemoglobin, renal function, and hematologic values are necessary to manage treatment effectiveness and side effects.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vitamin B12 deficiency
  • taste impairment
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • erythema
Show 3 more
  • pruritus
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is advisable to keep the storage temperature between 1 and 30 degrees Celsius at room temperature. This will help maintain the effectiveness of the medication over time.

Appearance and packaging

Appearance

White, oblong, extended-release film-coated tablet

Package unit

Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.